Leukemia Research
Volume 29, Issue 2 , Pages 173-178 , February 2005

Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-α

  • Kazuto Takeuchi

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
    • ,
  • Ikuya Sakai

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 89 960 5296; fax: +81 89 960 5299.
    • ,
  • Hirosi Narumi

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
    • ,
  • Masaki Yasukawa

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
    • ,
  • Kensuke Kojima

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
    • ,
  • Yoko Minamoto

      Affiliations

    • Department of Internal Medicine, Matsuyama Red Cross Hospital, Japan
    • ,
  • Tomoaki Fujisaki

      Affiliations

    • Department of Internal Medicine, Matsuyama Red Cross Hospital, Japan
    • ,
  • Kazushi Tanimoto

      Affiliations

    • Division of Hematology, Ehime Prefectural Central Hospital, Japan
    • ,
  • Masamichi Hara

      Affiliations

    • Division of Hematology, Ehime Prefectural Central Hospital, Japan
    • ,
  • Akihiko Numata

      Affiliations

    • Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Japan
    • ,
  • Hisashi Gondo

      Affiliations

    • Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Japan
    • ,
  • Masuhiro Takahashi

      Affiliations

    • School of Health Science Medical Laboratory Science, Niigata University Faculty of Medicine, Japan
    • ,
  • Nobuharu Fujii

      Affiliations

    • Department of Internal Medicine II, Okayama University Medical School, Japan
    • ,
  • Kozo Masuda

      Affiliations

    • Department of Internal Medicine II, Okayama University Medical School, Japan
    • ,
  • Shigeru Fujita

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan

Received 22 March 2004 ,Accepted 8 June 2004.

References 

  1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497
  2. Koeffler HP, Golde DW. Chronic myelogenous leukemia—new concepts. N Engl J Med. 1981;304:1201–1209
  3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–3356
  5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042
  7. Drummond MW, Holyoake TL. Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?. Blood Rev. 2001;15:85–95
  8. Gresser I. Antitumor effects of interferons: past, present and future. Br J Haematol. 1991;79(supp1):1–5
  9. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198–1205
  10. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-alpha in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–1069
  11. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic response in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532–538
  12. Kantarjian HM, O’Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069–3081
  13. Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254–261
  14. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood. 2002;100:2926–2931
  15. Kim YJ, Kim DW, Lee S, Kim HJ, Kim YL, Hwang JY, et al. Complihensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol. 2002;68:272–280
  16. Grunau C, Clark SJ, Rosethal A. Bisulfite genomic sequencing:systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001;29:E65–5
  17. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003;100:14133–14138
  18. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weiber A, Goldman JM, Melo JV. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia:possible inadequancy of a feedback mechanism. Blood. 2002;99:1766–1775
  19. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signaling. Nature. 1997;387:917–921
  20. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 1999;96:12804–12809
  21. Zhang X, Ren R. BCR-ABL efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel modelfor chronic myelogenous leukemia. Blood. 1998;92:3829–3840
  22. Singal R, Ginder GD. DNA methylation. Blood. 1999;93:4059–4070
  23. Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis. 2000;21:461–467
  24. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687–692
  25. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29–35
  26. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101:2784–2788
  27. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukemia. Br J Haematol. 2003;123:654–661
  28. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995;86:1548–1556
  29. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, et al. Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res. 2001;61:8331–8339

PII: S0145-2126(04)00237-1

doi: 10.1016/j.leukres.2004.06.006

Leukemia Research
Volume 29, Issue 2 , Pages 173-178 , February 2005

Article Tools

* Image Usage & Resolution